Fishing for new drugs

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 7780-7782

  Calvert, Alan Hilary ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEHYDRODIDEMNIN B; DIDEMNIN A; DIDEMNIN B; DOLASTATIN; NATURAL PRODUCT; PACLITAXEL; DEPSIPEPTIDE; NEW DRUG;

ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BREAST CANCER; CANCER; CANCER MODEL; CANCER RESEARCH; CARDIOTOXICITY; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG ISOLATION; EDITORIAL; EXPERIMENTAL MODEL; FATIGUE; HUMAN; MUSCLE CRAMP; MUSCLE TOXICITY; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; STOMACH CANCER; TAXUS BREVIFOLIA; NEOPLASM; NOTE;

DEPSIPEPTIDES; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS;

EID: 32944459313     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.004     Document Type: Editorial

References (28)

1. Cilliers L, Retief FP: Poisons, poisoning and the drug trade in ancient Rome. Akroterion 45:88-100, 2000
2. Faivre S, Chièze S, Delbaldo C, et al: Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide, administered as a 24-hour infusion every 2 weeks in patients with advanced malignancies. J Clin Oncol 23:7871-7880, 2005
3. Rinehart KL Jr, Gloer JB, Hughes RG, et al: Didemnins: Antiviral and antitumour depsipeptides from a Caribbean tunicate. Science 212:933-935, 1981
4. Dorr FA, Kuhn JG, Phillips J, Vonhoff DD: Phase-I clinical and pharmacokinetic investigation of didemnin-B, a cyclic depsipeptide. Eur J Cancer Clin Oncol 24:1699-1706, 1988
5. Shin DM, Holoye PY, Murphy WK, et al: Phase-I/II clinical trial of didemnin-B in non-small-cell lung cancer: Neuromuscular toxicity is dose-limiting. Cancer Chemother Pharmacol 29:145-149, 1991
6. Kucuk O, Young ML, Habermann, et al: Phase II trial of didemnin B in previously treated non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group (ECOG) study. Am J Clin Oncol Cancer Clinical Trials 23:273-277, 2000
7. Mittelman A, Chun HG, Puccio C, et al: Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319). Invest New Drugs 17:179-182, 1999
8. Hochster H, Oratz R, Ettinger DS, et al: A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: An Eastern Cooperative Oncology Group study (PB687). Invest New Drugs 16:259-263, 1998
9. Malfetano JH, Blessing JA, Homesley HD: A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix a gynecologic oncology group study: A gynecologic oncology group study. Am J Clin Oncol Cancer Clin Trials 19:184-186, 1996
10. Shin DM, Holoye PY, Forman A, et al: Phase II clinical-trial of didemnin-b in previously treated small-cell lung-cancer. Invest New Drugs 12:243-249, 1994
11. Weiss RB, Peterson BL, Allen SL, et al: A phase II trial of didemnin-b in myeloma. Invest New Drugs 12:41-43, 1994
12. Malfetano JH, Blessing JA, Jacobs AJ: A Phase-II trial of didemnin-B (NSC #335319) in patients with previously treated epithelial ovarian cancer: A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clinical Trials 16:47-49, 1993
13. Jones DV, Ajani JA, Blackburn R, et al: Phase II study of didemnin-B in advanced colorectal cancer. Invest New Drugs 10:211-213, 1992
14. Benvenuto JA, Newman RA, Bignanni GS, et al: Phase II clinical and pharmacological study of didemnin-B in patients with metastatic breast cancer. Invest New Drugs 10:113-117, 1992
15. Taylor SA, Goodman P, Crawford ED, et al: Phase II evaluation of didemnin-B in advanced adenocarcinoma of the kidney: A Southwest Oncology Group Study. Investigational New Drugs 10:55-56, 1992
16. Sakai R, Rinehart KL Jr, Kishore V, et al: Structure activity relationships of the didemnins. J Med Chem 39:2819-2834, 1996
17. Rinehart KL: Antitumour compounds from tunicates. Med Res Rev 20:1-27, 2000
18. Russell DH, Buckley AR, Montgomery DW, et al: Prolactin-dependent mitogenesis in Nb 2 node lymphoma cells: Effects of immunosuppressive cyclopetpides. J Immunol 138:276-284, 1987
19. Ahuja D, Geiger A, Ramanjulu JM, et al: Inhibition of protein synthesis by didemnins: Cell Potency and SAR. J Med Chem 43:4212-4218, 2000
20. Crews CM, Collins JL, Lane WS, et al: GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1α. J Biol Chem 269:15411-15414, 1994
21. Fernández G, Losada A, Alcaide V, et al: Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C. 21:7533-7544, 2002
22. Cuadrado A, González L, Suárez Y, et al: JNK activation is critical for aplidine-induced apoptosis. Oncogene 23:4673-4680, 2003
23. Broggini M, Marchini SV, Galleria E, et al: Aplidine, a new anticancer agent of marine origin, inhibits vascular entothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukaemia cells MOLT-4. Leukaemia 17:52-59, 2003
24. Erba E, Serafini M, Gaipa G, et al: Effect of aplidin in acute lymphoblastic leukaemia cells. Br J Cancer 89:763-773, 2003
25. Gajate C, An F, MollinedoF: Rapid and selective apoptosis in human leukemic cells induced by aplidine through a Fas/CD95- and mitochondrial- mediated mechanism. Clin Cancer Res 9:1535-1545, 2003
26. Bresters D, Broekhuizen AJF, Kaaijk P, et al: In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: A rational basis for clinical development. Leukemia 17:1338-1343, 2003
27. Niyikiza C, Baker SD, Seitz DE, et al: Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552, 2002
28. Janne PA, Engelman JA, Johnson BE: Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 23:3227-3234, 2005